These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 9194591)

  • 1. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
    Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
    Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
    Tee YT; Wang PH; Tsai HT; Lin LY; Lin HT; Yang SF; Hsieh YH; Ying TH
    J Surg Oncol; 2012 Aug; 106(2):204-8. PubMed ID: 22354580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
    Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
    Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.
    Su CK; Yeh KT; Yeh CB; Wang PH; Ho ES; Chou MC; Liu KC; Yang SF; Yi YC
    J Surg Oncol; 2011 Dec; 104(7):755-9. PubMed ID: 21761413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T; Blasi F; Talarico D
    Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
    Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
    Cancer Res; 1995 Sep; 55(18):3958-63. PubMed ID: 7664262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.